Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Canakinumab in Active, Refractory Urticarial Vasculitis
NCT01170936Phase 2Completed
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Jul 2010
- Primary completion
- Sep 2011
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of canakinumab in urticarial vasculitis (UV), sponsored by Charité – Universitätsmedizin Berlin. Started Jul 2010; status: completed.
02
Drugs
canakinumab
03
Conditions
urticarial vasculitis (UV)
Beyond the preview
Go deeper on NCT01170936.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01170936.